NSCLC (Non-small Cell Lung Carcinoma) Enrolling by Invitation Phase 2 Trials for Regorafenib (DB08896)

IndicationStatusPhase
DBCOND0103105 (NSCLC (Non-small Cell Lung Carcinoma))Enrolling by Invitation2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02955940An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibTreatment